PARIS: Ipsen and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. The anticipated acquisition is focused on the lead Phase I/II program ICT01 in first line acute myeloid…
LONDON: N4 Pharma plc (AIM: N4P), a UK-based biotechnology company developing its proprietary Nuvec® gene delivery system for advanced cancer and disease therapies, announced its audited financial results for the year ended Dec. 31, 2024. The company’s annual report and notice of its annual general meeting (AGM) have been distributed to shareholders. The AGM…